CompletedPhase 2NCT00471614

Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine

Studying NON RARE IN EUROPE: Metabolic syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Center for Complementary and Integrative Health (NCCIH)
Principal Investigator
Morris Schambelan, MD
University of California, San Francisco
Intervention
NucleomaxX (contains uridine)(drug)
Enrollment
3 enrolled
Eligibility
18-65 years · All sexes
Timeline
20072012

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00471614 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Metabolic syndrome

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Metabolic syndrome

← Back to all trials